 |
7 Diseases |  |
0 Trials |
|
0 Trials |  |
32 News |  |
- || desidustat (ZYAN 1) / Zydus Cadila
Review, Journal: Desidustat: First Approval. (Pubmed Central) - Aug 27, 2022
Desidustat is in clinical development in China for the treatment of anaemia in patients with CKD, in Mexico for the management of COVID-2019 infections and in the USA for the treatment of chemotherapy induced anaemia. This article summarizes the milestones in the development of desidustat leading to this first approval for anaemia associated with CKD.
- | desidustat (ZYAN 1) / Zydus Cadila, Zyrop (recombinant human erythropoietin biosimilar) / Zydus Cadila
Journal: Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state. (Pubmed Central) - May 17, 2022
Desidustat also maintained normal hemoglobin levels after cessation of rhEPO treatment. Thus, novel prolyl hydroxylase inhibitor desidustat can treat EPO resistance via improved iron utilization and decreased inflammation.
- | desidustat (ZYAN 1) / Zydus Cadila
Journal: Prolyl hydroxylase inhibitor desidustat protects against acute and chronic kidney injury by reducing inflammatory cytokines and oxidative stress. (Pubmed Central) - Apr 5, 2022
Desidustat treatment also reduced renal fibrosis as observed by histological analysis and hydroxyproline content. Desidustat treatment reduced the renal fibrosis and inflammation along with a reduction in anemia in preclinical models of kidney injury, which may translate to protective effects in CKD patients.